More Data to Inform the PPI−Dementia Controversy

October 12, 2017

More Data to Inform the PPI−Dementia Controversy

  1. Allan S. Brett, MD

In this latest study, proton-pump inhibitors were not associated with cognitive impairment.

  1. Allan S. Brett, MD

Patients continue to express concern about media reports stating that proton-pump inhibitor (PPI) use might cause cognitive impairment or dementia. In this latest study, researchers took advantage of prospectively collected data on 10,500 patients (mean age, 73) with normal cognition or mild cognitive impairment who were followed at 33 U.S. Alzheimer disease research centers. Participants underwent detailed structured cognitive assessments annually and were classified as using PPIs continuously, intermittently, or never. Follow-up ranged from 2 to 6 years.

In analyses adjusted for confounding demographic and clinical variables, PPI use (continuous or intermittent) compared with no PPI use was associated with significantly lower risk for progression from normal cognition to mild cognitive impairment, and from mild cognitive impairment to dementia. Hazard ratios for progression were roughly 0.80 for these outcomes. Histamine-2–receptor antagonist use also was associated with lower risk for cognitive impairment.


This study's strength is its robust longitudinal assessment of cognitive status at specialized research centers; in contrast, the first publicized study to suggest a PPI−dementia connection was derived from an administrative claims database with nonverified dementia diagnoses and inadequate adjustment for confounding variables (NEJM JW Gen Med Jun 15 2016 and JAMA Neurol 2016; 73:410). Although the protective effect of PPIs against cognitive decline found in the current study is difficult to explain, the findings provide reassurance that PPIs are unlikely to cause cognitive decline. A recent Finnish study with confirmation of dementia diagnoses reached similar conclusions (NEJM JW Gen Med Sep 15 2017 and J Gastroenterol 2017 Jul 11; [e-pub]).

Editor Disclosures at Time of Publication

  • Disclosures for Allan S. Brett, MD at time of publication Nothing to disclose


Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.